Claims for Patent: 11,510,942

Summary for Patent: 11,510,942

Title:	Stable, highly pure L-cysteine compositions for injection and methods of use
Abstract:	The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cysteine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
Inventor(s):	John Maloney, Aruna Koganti, Phanesh Koneru
Assignee:	Exela Pharma Sciences LLC
Application Number:	US17/188,922
Patent Claims:	1. A composition for injection comprising a mixture of: a L-cysteine composition, wherein the L-cysteine composition contributes to the composition for injection: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; not more than 250 mcg/L of aluminum; and not more than 2.0 wt % L-cysteine relative to L-cysteine; one or more amino acids selected from the group consisting of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine, tryptophan, alanine, arginine, glycine, proline, serine, and tyrosine; and, an intravenous fluid. 2. The composition for injection of claim 1, wherein the L-cysteine composition provides not more than 0.8 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 3. The composition for injection of claim 1, wherein the L-cysteine composition provides not more than 0.6 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 4. The composition for injection of claim 1, wherein the L-cysteine composition provides not more than 0.4 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 5. The composition for injection of claim 1, wherein the L-cysteine composition provides not more than 0.21 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 6. The composition for injection of claim 1, wherein the composition for injection provides not more than 5 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 7. The composition for injection of claim 1, wherein the composition for injection provides not more than 4 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 8. The composition for injection of claim 1, wherein the composition for injection provides not more than 3 mcg/kg/day of aluminum when administered as part of a parenteral nutrition regimen. 9. The composition for injection of claim 1, wherein the intravenous fluid is selected from the group consisting of isotonic saline, glucose solution, glucose saline, dextrose solution, crystalline amino acid solution, and lipids, and combinations thereof. 10. The composition for injection of claim 9, wherein the intravenous fluid is selected from the group consisting of isotonic saline, dextrose solution, crystalline amino acid solution, and combinations thereof. 11. The composition for injection of claim 1, wherein the intravenous fluid comprises dextrose solution. 12. A composition for injection comprising a mixture of: a L-cysteine composition, wherein the L-cysteine composition contributes to the composition for injection: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount of about 50 mg/mL; not more than 120 ppb of aluminum; and not more than 1.0 wt % L-cysteine relative to L-cysteine; one or more amino acids selected from the group consisting of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine, tryptophan, alanine, arginine, glycine, proline, serine, and tyrosine; and, an intravenous fluid; wherein, the L-cysteine composition provides not more than 0.21 mcg/kg/day of aluminum, and the composition for injection provides not more than 5 mcg/kg/day of aluminum, when administered as part of a parenteral nutrition regimen. 13. The composition of claim 12, wherein the L-cysteine composition has a pH of about 1.0 to about 2.5. 14. The composition of claim 12, wherein the intravenous fluid comprises dextrose solution. 15. A method of treating a subject having an adverse health condition that is responsive to L-cysteine administration, said method comprising: parenterally administering to said subject a composition for injection comprising a mixture of: a L-cysteine composition, wherein the L-cysteine composition contributes to the composition for injection: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; not more than 250 mcg/L of aluminum; and not more than 2.0 wt % L-cysteine relative to L-cysteine; one or more amino acids selected from the group consisting of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine, tryptophan, alanine, arginine, glycine, proline, serine, and tyrosine; and, an intravenous fluid. 16. The method of claim 15, wherein the L-cysteine composition contributes to the composition for injection: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount of about 50 mg/mL; not more than 120 mcg/L of aluminum; and not more than 1.0 wt % L-cysteine relative to L-cysteine. 17. The method of claim 15, wherein said L-cysteine composition contributes aluminum in an amount less than 200 mcg/L. 18. The method of claim 15, wherein said L-cysteine composition contributes aluminum in an amount less than 150 mcg/L. 19. The method of claim 15, wherein said L-cysteine composition contributes aluminum in an amount less than 120 mcg/L. 20. The method of claim 15, wherein the intravenous fluid is selected from the group consisting of isotonic saline, glucose solution, glucose saline, dextrose solution, crystalline amino acid solution, and lipids, and combinations thereof. 21. The method of claim 20, wherein said intravenous fluid is selected from the group consisting of isotonic saline, dextrose solution, and crystalline amino acid solution, and combinations thereof. 22. The method of claim 21, wherein said intravenous fluid is dextrose solution. 23. The method of claim 15, wherein said administering comprises administration once or twice daily. 24. The method of claim 15, wherein said subject is an adult or has an age of 12 years to 17 years and said administering delivers about 15 nag of said L-cysteine per gram of said one or more amino acids. 25. The method of claim 15, wherein said subject is less than 12 years of age and said administering delivers about 5 mg of said L-cysteine per gram of said one or more amino acids. 26. The method of claim 15, wherein and said L-cysteine composition contributes not more than 0.21 mcg/kg/day of aluminum. 27. The method of claim 15, wherein and said composition for injection provides not more than 5 mcg/kg/day of aluminum. 28. The method of claim 15, wherein said adverse health condition results from the inability to convert methionine to L-cysteine. 29. The method of claim 15, wherein the adverse health condition is the need for parenteral nutrition. 30. A method of treating a subject having an adverse health condition that is responsive to L-cysteine administration, said method comprising: parenterally administering to said subject a composition comprising a mixture of: a L-cysteine composition, wherein the L-cysteine composition contributes to the composition for injection: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount of about 50 mg/mL; not more than 120 mcg/L of aluminum; and not more than 1.0 wt % L-cysteine relative to L-cysteine; one or more amino acids selected from the group consisting of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine, tryptophan, alanine, arginine, glycine, proline, serine, and tyrosine; and, an intravenous fluid; wherein, the L-cysteine composition provides not more than 0.21 mcg/kg/day of aluminum, and the composition for injection provides not more than 5 mcg/kg/day of aluminum, when administered as part of a parenteral nutrition regimen. 31. The method of claim 30, wherein said subject is an adult or has an age of 12 years to 17 years and said administering delivers about 15 mg of said L-cysteine per gram of said one or more amino acids. 32. The method of claim 30, wherein said subject is less than 12 years of age and said administering delivers about 5 mg of said L-cysteine per gram of said one or more amino acids. 33. The method of claim 32, wherein the adverse health condition is the need for parenteral nutrition. 34. A method of preparing a reduced aluminum composition for a parenteral nutrition regimen comprising L-cysteine, the method comprising: mixing a composition comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount of about 50 mg/mL; not more than 120 ppb of aluminum; and not more than 1.0% L-cysteine relative to L-cysteine; with, a composition comprising one or more amino acids selected from the group consisting of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine, tryptophan, alanine, arginine, glycine, proline, serine, and tyrosine; and, an intravenous fluid, to prepare the reduced aluminum composition for a parenteral nutrition regimen.